Not exact matches
Removal of the
bladder, or radical cystectomy (RC), is an effective treatment for locally
advanced bladder cancer, but complications occur in as many as 66 % of
patients.
It represents a real
advance in the second - line treatment of
advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these
patients.
«Nivolumab immunotherapy helps
patients with
advanced bladder cancer.»
Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail
patients with
advanced bladder cancer in early 2017.